Janux Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Janux Therapeutics, Inc. carries a market capitalization of 1.02B, placing it among publicly traded companies globally. Its enterprise value stands at -11.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.02B |
| Enterprise Value | -11.77M |
Share Statistics
Janux Therapeutics, Inc. currently has 61.08M shares outstanding.
| Shares Outstanding | 61.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 39.96, and the price-to-book ratio stands at 1.01.
| PE Ratio | N/A |
| PS Ratio | 39.96 |
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | -23.64 |
| P/OCF Ratio | -23.25 |
Enterprise Valuation
| EV / Sales | 50.31 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Janux Therapeutics, Inc. maintains a current ratio of 16.35, meaning it holds 16.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 16.35 |
| Quick Ratio | 16.25 |
| Debt / Equity | 2.26 |
| Debt / EBITDA | -0.15 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -10.70 |
| Return on Assets (ROA) | -10.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Janux Therapeutics, Inc.'s stock has declined approximately -26.97023% over the past 52 weeks. The 50-day moving average sits at 16.96, while the 200-day moving average is 14.96.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.97023% |
| 50-Day Moving Average | 16.96 |
| 200-Day Moving Average | 14.96 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Janux Therapeutics, Inc. generated 24.00M in revenue and converted that into -102.59M in net income, yielding earnings per share of -1.64. EBITDA reached -141.65M, while operating income came in at -143.55M.
| Revenue | 24.00M |
| Gross Profit | N/A |
| Operating Income | -143.55M |
| Pretax Income | -102.59M |
| Net Income | -102.59M |
| EBITDA | -141.65M |
| EBIT | -143.55M |
| Earnings Per Share (EPS) | -1.64 |
Balance Sheet
Janux Therapeutics, Inc. holds 970.91M in cash and equivalents against 20.99M in total debt, resulting in a net debt position of -27.77M. Total book value stands at 927.98M, with working capital of 923.19M providing operational flexibility.
| Cash & Cash Equivalents | 970.91M |
| Total Debt | 20.99M |
| Net Debt | -27.77M |
| Equity (Book Value) | 927.98M |
| Book Value Per Share | 15.19 |
| Working Capital | 923.19M |
Cash Flow
Janux Therapeutics, Inc. produced -41.25M in operating cash flow over the past twelve months. After subtracting -674,000.00 in capital expenditures, free cash flow totaled -41.92M - equivalent to -0.67 per share.
| Operating Cash Flow | -41.25M |
| Capital Expenditures | -674,000.00 |
| Free Cash Flow | -41.92M |
| FCF Per Share | -0.67 |
Margins
Janux Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -598.15 and net profit margin of -427.47 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -598.15 |
| Pretax Margin | -427.47 |
| Profit Margin | -427.47 |
| EBITDA Margin | -590.22 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.98 |
| FCF Yield | -4.23 |
Scores
Janux Therapeutics, Inc. posts an Altman Z-Score of 7.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.17 |